深度强化学习优化头颈癌降阶梯放疗的分次方案
本研究构建虚拟环境模拟放疗下肿瘤动态,用深度强化学习智能体优化分次方案,在5000例虚拟患者中比较个性化降阶梯计划与传统放疗。个性化分次使肿瘤剂量和危及器官生物有效剂量降低29%,平均危及器官BED减少5.61±2.96 Gy,预后结果几乎相同,低风险局部区域控制失败组占99.80%。
要点
- 基于患者反应的个性化分次可降低肿瘤剂量和危及器官BED 29%。
- 5000例虚拟患者中99.80%属于低风险局部区域控制失败组。
- 支持向量机决策边界可定义患者选择参数范围以应对模型不确定性。
核心结论
- 基于患者反应优化分次剂量可在头颈鳞癌中最小化毒性并维持局部区域控制。
- 对患者进行分层可减轻模型不确定性并降低治疗风险。
研究设计与样本
- 开发虚拟环境模拟放疗下肿瘤动态以优化剂量方案。
- 选择预测能维持局部区域控制的患者进行降阶梯实验。
- 使用增殖饱和指数和线性二次模型预测反应。
- 深度强化学习智能体通过与模拟环境交互优化分次方案,目标为降低危及器官生物有效剂量同时保持局部区域控制。
- 分析模型不确定性的影响,并使用支持向量机模型分割参数空间以识别对噪声更稳健的患者。
主要发现
- 在5000例虚拟患者队列中比较个性化降阶梯计划与传统放疗。
- 个性化分次使肿瘤剂量和危及器官生物有效剂量降低29%,平均危及器官BED减少5.61±2.96 Gy。
- 预后结果几乎相同,低风险局部区域控制失败组患者占99.80%。
- 模型不确定性影响剂量学指标和预后,但高BED获益组对噪声表现出更大稳健性。
- 支持向量机决策边界定义了患者选择的参数范围。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients with locally-advanced head and neck squamous cell carcinomas (HNSCCs), particularly those related to human papillomavirus (HPV), often achieve good locoregional control (LRC), yet they suffer significant toxicities from standard chemoradiotherapy. This study aims to optimize the daily dose fractionation based on individual responses to radiotherapy (RT), minimizing toxicity while maintaining a low risk of LRC failure. METHOD: A virtual environment was developed to simulate tumor dynamics under RT for optimizing dose schedules. Patients predicted to maintain LRC were selected for de-escalation experiments. The proliferation saturation index (PSI) and linear-quadratic model were used to predict responses. A deep reinforcement learning (DRL) agent optimized fractionation schemes by interacting with the simulation environment, aiming to reduce the OAR's biologically effective dose (BED) while preserving LRC. The impact of model uncertainty was analyzed and a support vector machine (SVM) model was used to segment parameter space and identify patients more robust to noise. RESULTS: Personalized de-escalation plans were compared to conventional RT in a cohort of 5000 virtual patients. Personalized fractionation reduced the tumor dose and OAR's BED by 29%, with an average OAR BED reduction of 5.61 ± 2.96 Gy. Prognostic outcomes were nearly identical, with 99.80% of patients in the low-risk LRC failure group. Model uncertainty impacted dosimetric indicators and prognosis, but the high-BED benefit group showed greater robustness to noise. SVM decision boundaries defined parameters range for patient selection. CONCLUSION: Optimizing fractionated doses based on patient responses minimizes toxicity while maintaining LRC in HNSCCs. Stratifying patients can mitigate model uncertainty and reduce treatment risks.
引用
- Yan Y, Sun X, Chen Y, et al. Optimizing fractionation schedules for de-escalation radiotherapy in head and neck cancers using deep reinforcement learning. Radiother Oncol. 2025. PMID: 40090417. doi:10.1016/j.radonc.2025.110833
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。